正海生物：公司宫腔修复膜及乳房补片产品的研发工作正在有序开展

Core Viewpoint - Zhenghai Biological (300653) announced on October 27 that the development of its intrauterine repair membrane and breast patch products is progressing smoothly, with plans for product registration and sales strategy based on market conditions [1] Group 1: Product Development - The intrauterine repair membrane product has completed clinical trials and is currently advancing through the product registration process [1] - The breast patch product is in the clinical summary stage [1] Group 2: Sales Strategy - The company will consider the development progress of both products and the market conditions of the corresponding application departments to formulate a sales plan [1] - The aim is to maximize the value of these products in driving revenue growth [1]